New Black Book Research flash survey of 427 hospital and health system security leaders finds 74% see EHR, AI and cloud vendors as their top emerging cyber risk, 63% report vendor-linked incidents in the last 24 months, and over half have suffered clinical disruption or downtime.
Read More
New collaboration helps IT and communications teams deliver secure, consistent, and engaging content across managed devices and displays - without adding technical complexity.
Read MoreEnterprise adoption accelerates as CXAI strengthens its position at the center of the workplace experience and enterprise Agentic AI markets
Read More
The acquisition solidifies SETO's control over U.S. importation, compliance, and national distribution-positioning the company to scale its brand portfolio with greater speed, efficiency, and market access.
Read More100% of patients in Cohorts 1-3 remain free of cytokine release syndrome
CRIS-7-derived CD3 design underpins a controlled T-cell response, supporting the differentiated safety profile, combinability with standard of care
Read More
Aurora Sustainable Lands and Anew Climate combine proven land stewardship and innovative, technology-driven carbon quantification to deliver verifiable climate benefits
Read More
As Nigeria modernises one of Africa's largest public sector workforces, MuchSkills' technology is being deployed by Phillips Consulting to power a federal skills intelligence effort.
Read MoreProspectus Supplement and Base Shelf Prospectus are Accessible Through SEDAR+
NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR THE DISSEMINATION, DISTRIBUTION, RELEASE OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES
Read MoreJaguar CEO Lisa Conte presenting December 10 from 3:25pm - 3:35pm Eastern at the Emerging Growth Conference to provide updates on near-term catalysts; Click here to register
Initial results of ongoing investigator-initiated proof-of-concept trial demonstrate crofelemer can potentially extend the lives of infants born with intestinal failure due to microvillus inclusion disease (MVID), reducing the volume of the total parenteral support (PS) necessary for them to survive, though with associated toxicity; Groundbreaking PS reduction of up to 37%; No approved treatments exist for MVID
Company completed meeting with FDA October 2, 2025 for advice on advancing its ongoing placebo-controlled trial of crofelemer in support of possible expedited approval pathway for crofelemer for treatment of MVID
Read More
